Best Practice & Research Clinical Rheumatology
Volume 21, Issue 4 , Pages 713-732 , August 2007

Outpatient assessment of systemic vasculitis

  • Raashid Luqmani, DM, FRCP, FRCPE (Consultant Rheumatologist and Senior Lecturer)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 01865 727807.

References 

  1. Kussmaul A, Maier R. Ueber eine bisher nicht beshriebene eigenthümliche Arterienerkrangkung (Periarteritis Nodosa), die mit Morbus Brightii und rapid fortschreitender allegemeiner Muskellähmung einhergeht. Deutsches Archiv für klinische Medizin. 1866;(1):484–518
  2. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis and Rheumatism. 2000 May;43(5):1021–1032
  3. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis and Rheumatism. 2005 Feb 15;53(1):93–99
  4. Watts RA, Gonzalez-Gay MA, Lane SE, et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Annals of the Rheumatic Diseases. 2001 Feb;60(2):170–172
  5. Yanagawa H, Nakamura Y, Yashiro M, et al. Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999–2002. Pediatrics International. 2006 Aug;48(4):356–361
  6. Lie JT. Nomenclature and classification of vasculitis: plus ca change, plus c'est la meme chose. Arthritis and Rheumatism. 1994 Feb;37(2):181–186
  7. Zeek PM. Periarteritis nodosa; a critical review. American Journal of Clinical Pathology. 1952 Aug;22(8):777–790
  8. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis and Rheumatism. 1994 Feb;37(2):187–192
  9. Bloch DA, Michel BA, Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis and Rheumatism. 1990 Aug;33(8):1068–1073
  10. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis and Rheumatism. 1990 Aug;33(8):1135–1136
  11. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis and Rheumatism. 1990 Aug;33(8):1065–1067
  12. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Annals of Internal Medicine. 1998 Sep 1;129(5):345–352
  13. Heller I, Isakov A, Topilsky M. American College of Rheumatology Criteria for the diagnosis of vasculitis. Annals of Internal Medicine. 1999 May 18;130(10):861;(author reply 2)
  14. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Annals of the Rheumatic Diseases. 2007 Feb;66(2):222–227
  15. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). British Medical Journal. 1958 Aug 2;(5091):265–270
  16. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Annals of Internal Medicine. 1983 Jan;98(1):76–85
  17. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford). 2002 May;41(5):572–581
  18. Rihova Z, Jancova E, Merta M, et al. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney & Blood Pressure Research. 2005;28(3):144–152
  19. Slot MC, Tervaert JW, Franssen CF, Stegeman CA. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney International. 2003 Feb;63(2):670–677
  20. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis and Rheumatism. 1997 Feb;40(2):371–380
  21. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney International. 1998 Mar;53(3):743–753
  22. Specks U, Wheatley CL, McDonald TJ, et al. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. Mayo Clinic Proceedings. 1989 Jan;64(1):28–36
  23. Luqmani RA, Bacon PA, Beaman M, et al. Classical versus non-renal Wegener's granulomatosis. The Quarterly Journal of Medicine. 1994 Mar;87(3):161–167
  24. Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. American Journal of Kidney Diseases. 2006 Jan;47(1):15–23
  25. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM: Monthly Journal of the Association of Physicians. 1994 Nov;87(11):671–678
  26. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis and Rheumatism. 2001 Apr;44(4):912–920
  27. Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM: Monthly Journal of the Association of Physicians. 1997 Jun;90(6):391–399
  28. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. The Journal of Rheumatology. 2003 Jan;30(1):80–88
  29. Koutantji M, Harrold E, Lane SE, et al. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis and Rheumatism. 2003 Dec 15;49(6):826–837
  30. Hoffman GS, Drucker Y, Cotch MF, et al. Wegener's granulomatosis: patient-reported effects of disease on health, function, and income. Arthritis and Rheumatism. 1998 Dec;41(12):2257–2262
  31. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. The New England Journal of Medicine. 2003 Jul 3;349(1):36–44
  32. Sparsa A, Liozon E, Wechsler J, et al. Aortic angiosarcoma clinically mimicking polyarteritis nodosa. Scandinavian Journal of Rheumatology. 2006 May–Jun;35(3):237–240
  33. McGuire BB, O'Brien MF, Akhtar M, Fitzpatrick JM. Testicular vasculitis mimicking a testicular neoplasm. Irish Medical Journal. 2006 Jan;99(1):27–28
  34. Diez-Porres L, Rios-Blanco JJ, Robles-Marhuenda A, et al. ANCA-associated vasculitis as paraneoplastic syndrome with colon cancer: a case report. Lupus. 2005;14(8):632–634
  35. Hutson TE, Hoffman GS. Temporal concurrence of vasculitis and cancer: a report of 12 cases. Arthritis Care and Research. 2000 Dec;13(6):417–423
  36. Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford). 2004 Dec;43(12):1532–1535
  37. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Annals of Internal Medicine. 1992 Mar 15;116(6):488–498
  38. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999 Jan;78(1):26–37
  39. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Annals of Internal Medicine. 1996;124(5):477–484
  40. Smetana GW, Shmerling RH. Does this patient have temporal arteritis?. JAMA: The Journal of the American Medical Association. 2002 Jan 2;287(1):92–101
  41. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis and Rheumatism. 1998;41(9):1521–1537
  42. Wiik AS. Clinical use of serological tests for antineutrophil cytoplasmic antibodies. What do the studies say?. Rheumatic Diseases Clinics of North America. 2001 Nov;27(4):799–813vi–vii
  43. Langford CA. The diagnostic utility of c-ANCA in Wegener's granulomatosis. Cleveland Clinic Journal of Medicine. 1998;65(3):135–140
  44. Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis and Rheumatism. 1993;36(3):365–371
  45. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis and Rheumatism. 2000;43(9):2025–2033
  46. Choi YH, Im JG, Han BK, et al. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest. 2000 Jan;117(1):117–124
  47. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Current Rheumatology Reports. 2004 Jun;6(3):203–211
  48. Waggoner AD, Harris KM, Braverman AC, et al. The role of transthoracic echocardiography in the management of patients seen in an outpatient cardiology clinic. Journal of the American Society of Echocardiography. 1996 Nov–Dec;9(6):761–768
  49. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004 Dec;114(6):1708–1733
  50. Lee MH, Dai ZK, Lee MS, et al. The recommended frequency of echocardiography in follow-up evaluation of patients with Kawasaki disease. Acta Paediatrica Taiwanica. 2005 Nov–Dec;46(6):346–351
  51. Baer AZ, Rubin LG, Shapiro CA, et al. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. Archives of Pediatrics & Adolescent Medicine. 2006 Jul;160(7):686–690
  52. Espinola-Zavaleta N, Soto ME, Bauk L, et al. Coronary reserve in Takayasu's arteritis: transesophageal echocardiographic analysis. Echocardiography. 2005 Aug;22(7):593–598
  53. Bezerra Lira-Filho E, Campos O, Lazaro Andrade J, et al. Thoracic aorta evaluation in patients with Takayasu's arteritis by transesophageal echocardiography. Journal of the American Society of Echocardiography. 2006 Jun;19(6):829–834
  54. Korantzopoulos P, Papaioannides D, Siogas K. The heart in Wegener's granulomatosis. Cardiology. 2004;102(1):7–10
  55. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Annals of Internal Medicine. 2005 Mar 1;142(5):359–369
  56. Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. The New England Journal of Medicine. 1997 Nov 6;337(19):1336–1342
  57. Schmidt WA, Natusch A, Moller DE, et al. Involvement of peripheral arteries in giant cell arteritis: a color Doppler sonography study. Clinical and Experimental Rheumatology. 2002 May–Jun;20(3):309–318
  58. Kissin EY, Merkel PA. Diagnostic imaging in Takayasu arteritis. Current Opinion in Rheumatology. 2004 Jan;16(1):31–37
  59. Lohrmann C, Uhl M, Warnatz K, et al. Sinonasal computed tomography in patients with Wegener's granulomatosis. Journal of Computer Assisted Tomography. 2006 Jan–Feb;30(1):122–125
  60. Benoudiba F, Marsot-Dupuch K, Rabia MH, et al. Sinonasal Wegener's granulomatosis: CT characteristics. Neuroradiology. 2003 Feb;45(2):95–99
  61. Lloyd G, Lund VJ, Beale T, Howard D. Rhinologic changes in Wegener's granulomatosis. The Journal of Laryngology and Otology. 2002 Jul;116(7):565–569
  62. Lohrmann C, Uhl M, Kotter E, et al. Pulmonary manifestations of wegener granulomatosis: CT findings in 57 patients and a review of the literature. European Journal of Radiology. 2005 Mar;53(3):471–477
  63. Lee KS, Kim TS, Fujimoto K, et al. Thoracic manifestation of Wegener's granulomatosis: CT findings in 30 patients. European Radiology. 2003 Jan;13(1):43–51
  64. Stangou M, Asimaki A, Bamichas G, et al. Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: a single-center experience. Journal of Nephrology. 2005 Jan–Feb;18(1):35–44
  65. Pesci A, Pavone L, Buzio C, Manganelli P. Respiratory system involvement in ANCA-associated systemic vasculitides. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases. 2005 Dec;22(supplement 1):S40–S48
  66. Lohrmann C, Uhl M, Schaefer O, et al. Serial high-resolution computed tomography imaging in patients with Wegener granulomatosis: differentiation between active inflammatory and chronic fibrotic lesions. Acta Radiologica. 2005 Aug;46(5):484–491
  67. Summers RM, Aggarwal NR, Sneller MC, et al. CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis. Chest. 2002 Jan;121(1):242–250
  68. Gotway MB, Araoz PA, Macedo TA, et al. Imaging findings in Takayasu's arteritis. AJR. American Journal of Roentgenology. 2005 Jun;184(6):1945–1950
  69. Paul JF, Fiessinger JN, Sapoval M, et al. Follow-up electron beam CT for the management of early phase Takayasu arteritis. Journal of Computer Assisted Tomography. 2001 Nov–Dec;25(6):924–931
  70. Kanamaru H, Sato Y, Takayama T, et al. Assessment of coronary artery abnormalities by multislice spiral computed tomography in adolescents and young adults with Kawasaki disease. The American Journal of Cardiology. 2005 Feb 15;95(4):522–525
  71. Wagner AD, Andresen J, Raum E, et al. Standardised work-up programme for fever of unknown origin and contribution of magnetic resonance imaging for the diagnosis of hidden systemic vasculitis. Annals of the Rheumatic Diseases. 2005 Jan;64(1):105–110
  72. Tso E, Flamm SD, White RD, et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis and Rheumatism. 2002 Jun;46(6):1634–1642
  73. Andrews J, Al-Nahhas A, Pennell DJ, et al. Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Annals of the Rheumatic Diseases. 2004 Aug;63(8):995–1000
  74. Bley TA, Wieben O, Uhl M, et al. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR. American Journal of Roentgenology. 2005 Jan;184(1):283–287
  75. Bley TA, Weiben O, Uhl M, et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis and Rheumatism. 2005 Aug;52(8):2470–2477
  76. Narvaez J, Narvaez JA, Nolla JM, et al. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology (Oxford). 2005 Apr;44(4):479–483
  77. Greil GF, Stuber M, Botnar RM, et al. Coronary magnetic resonance angiography in adolescents and young adults with kawasaki disease. Circulation. 2002 Feb 26;105(8):908–911
  78. Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis and Rheumatism. 2006 Feb 15;55(1):131–137
  79. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Current Opinion in Rheumatology. 2005 Jan;17(1):9–15
  80. Kobayashi Y, Ishii K, Oda K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. Journal of Nuclear Medicine. 2005 Jun;46(6):917–922
  81. Walter MA, Melzer RA, Schindler C, et al. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. European Journal of Nuclear Medicine and Molecular Imaging. 2005 Jun;32(6):674–681
  82. Webb M, Chambers A, AL-Nahhas A, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. European Journal of Nuclear Medicine and Molecular Imaging. 2004 May;31(5):627–634
  83. The Royal College of Physicians , The Bone and Tooth Society of Great Britain , The National Osteoporosis Society . Glucocorticoid-induced Osteoporosis. Sudbury: The Lavenham Press Ltd.; 2002;
  84. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis and Rheumatism. 2001 Jul;44(7):1496–1503
  85. Herlyn K, Hoder J, Gross WL, Reinhold-Keller E. Scientifically based patient education exemplified by patients with primary systemic vasculitis. The vasculitis patient education program–development, contents and initial results of evaluation. Zeitschrift für Rheumatologie. 2002 Feb;61(1):13–20
  86. Luqmani RA, Pathare S, Kwok-Fai TL. How to diagnose and treat secondary forms of vasculitis. Best Practice & Research. Clinical Rheumatology. 2005 Apr;19(2):321–336
  87. Hogan SL, Nachman PH, Wilkman AS, et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. Journal of the American Society of Nephrology. 1996 Jan;7(1):23–32
  88. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrology, Dialysis, Transplantation. 2001 Oct;16(10):2018–2027
  89. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism. 2005 Aug;52(8):2461–2469
  90. Gaskin G, Jayne D. Adjunctive Plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. Journal of the American Society of Nephrology. 2002;13:F-FC010
  91. Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis and Rheumatism. 1992 Feb;35(2):208–215
  92. Guillevin L, Lhote F, Jarrousse B, et al. Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients. Annales de Médecine Interne. 1992;143(supplement 1):63–74
  93. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. The New England Journal of Medicine. 1994 Mar 17;330(11):751–756
  94. Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. The Journal of Pediatrics. 2006 Aug;149(2):241–247
  95. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism. 2002 May;46(5):1309–1318
  96. Vanoli M, Daina E, Salvarani C, et al. Takayasu's arteritis: A study of 104 Italian patients. Arthritis and Rheumatism. 2005 Feb 15;53(1):100–107

PII: S1521-6942(07)00005-8

doi: 10.1016/j.berh.2007.01.004

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 4 , Pages 713-732 , August 2007

Article Tools

* Image Usage & Resolution